Funding Opportunity PAR-25-326 from the NIH Guide for Grants and Contracts. The purpose of this NOFO is to provide investigators with a mechanism to access contract research/medical organizations (CROs/CMOs) and subject matter experts (SMEs) within the NINDS Ultra-Rare Gene-based Therapy (URGenT) Network to support planning, manufacturing, and limited nonclinical therapeutic development efforts.

GBP 34,866.00 - 45,163.00 per year: University of Cambridge: Do you have great analytical and IT skills? Interested in a role aiming to improve lives? Looking for your next challenge? We are recruiting a Genom Cambridge, United Kingdom

Funding Opportunity RFA-DA-25-078 from the NIH Guide for Grants and Contracts. This RFA will act as a parent RFA for the HEAL initiative Translation to Practice Team, specifically encouraging translational dissemination and implementation research focused on addressing overdose deaths and the intersection of pain and OUD. This RFA will function in tandem with targeted NOSIs that announce more specific areas of focus. For FY25, this currently includes the Workforce NOSI, the Exposure to Violence NOSI, and the Leveraging Inpatient Hospitalizations NOSI. It has a companion R33 RFA.

Funding Opportunity RFA-DA-25-077 from the NIH Guide for Grants and Contracts. This RFA will act as a parent RFA for the HEAL initiative Translation to Practice Team, specifically encouraging translational dissemination and implementation research focused on addressing overdose deaths and the intersection of pain and OUD. This RFA will function in tandem with targeted NOSIs that announce more specific areas of focus. For FY25, this currently includes the Workforce NOSI, the Exposure to Violence NOSI, and the Leveraging Inpatient Hospitalizations NOSI. It has a companion R61/R33 RFA.

Notice NOT-NS-25-012 from the NIH Guide for Grants and Contracts

Notice NOT-GM-25-015 from the NIH Guide for Grants and Contracts

Notice NOT-OD-25-046 from the NIH Guide for Grants and Contracts

Notice NOT-OD-25-050 from the NIH Guide for Grants and Contracts

Notice NOT-OD-25-047 from the NIH Guide for Grants and Contracts

Notice NOT-OD-25-048 from the NIH Guide for Grants and Contracts

Notice NOT-OD-25-052 from the NIH Guide for Grants and Contracts

Notice NOT-CA-25-001 from the NIH Guide for Grants and Contracts

Notice NOT-CA-25-023 from the NIH Guide for Grants and Contracts

Notice NOT-OD-25-045 from the NIH Guide for Grants and Contracts

Notice NOT-MD-25-007 from the NIH Guide for Grants and Contracts

Notice NOT-CA-25-024 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-DC-25-004 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity (NOFO) solicits R01 grant applications that propose independent research projects that are within the scientific mission areas of the National Institute on Deafness and Other Communication Disorders (NIDCD). This program is intended to support Early Stage and New Investigators from diverse backgrounds, including those from groups underrepresented in the health-related sciences. Investigators from diverse backgrounds, including those from underrepresented groups (e.g., see NOT-OD-20-031, Notice of NIHs Interest in Diversity), are encouraged to work with their institutions to apply. Preliminary data are not required for this NOFO.

Notice NOT-OD-25-049 from the NIH Guide for Grants and Contracts

Notice NOT-HS-25-009 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-DK-25-023 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity (NOFO) requests applications for the Hematology Central Coordinating Center (HCCC) for the NIDDK Hematology Centers Program. The HCCC is expected to work collaboratively with 4-5 Cooperative Centers of Excellence in Hematology (CCEHs) as part of the NIDDK Hematology Centers Program and serve as a national resource for the larger nonmalignant hematology research community. The HCCC will provide central administrative and communications support for the NIDDK Hematology Centers Program and operate a Pilot and Feasibility Program, supporting pilot research studies that will lead to larger research projects. All activities within the Program are expected to address the overall goal of supporting the national multidisciplinary research effort to combat nonmalignant hematologic diseases and/or tostudy normal hematopoiesis.